Cargando…

Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study

INTRODUCTION: Sublingual immunotherapy (SLIT) with birch pollen extract has been shown to be an efficacious treatment of allergic rhinitis (AR). An as-yet unanswered question is whether and how clinical benefit translates into patient benefit, i.e. what benefit patients derive from this treatment. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Blome, Christine, Hadler, Meike, Karagiannis, Efstrathios, Kisch, Julia, Neht, Christopher, Kressel, Nora, Augustin, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467431/
https://www.ncbi.nlm.nih.gov/pubmed/32342352
http://dx.doi.org/10.1007/s12325-020-01345-7
_version_ 1783578011843428352
author Blome, Christine
Hadler, Meike
Karagiannis, Efstrathios
Kisch, Julia
Neht, Christopher
Kressel, Nora
Augustin, Matthias
author_facet Blome, Christine
Hadler, Meike
Karagiannis, Efstrathios
Kisch, Julia
Neht, Christopher
Kressel, Nora
Augustin, Matthias
author_sort Blome, Christine
collection PubMed
description INTRODUCTION: Sublingual immunotherapy (SLIT) with birch pollen extract has been shown to be an efficacious treatment of allergic rhinitis (AR). An as-yet unanswered question is whether and how clinical benefit translates into patient benefit, i.e. what benefit patients derive from this treatment. METHODS: This 1-year, open, prospective, multicenter, non-interventional study conducted in 75 German centers measured patient-relevant benefit of birch pollen SLIT (Staloral(®) Birch) using the questionnaire “Patient Benefit Index for Allergic Rhinitis (PBI-AR)”. At treatment onset, patients rated the importance of 25 treatment needs; after the first birch pollen season on treatment, goal achievement was evaluated. A preference-weighted benefit index was calculated and its association with gender, asthma, allergy status, and severity of AR symptoms was determined. RESULTS: Mean age of the 291 adult patients was 38.8 years; 58.4% were female. The most important treatment goals were to “be able to stay outdoors without symptoms” (87.3% quite or very important), “no longer have a runny or stuffed-up nose” (86.9%), and “be able to breathe through your nose more freely” (86.9%). The treatment goals with the highest benefit ratings (referring to those patients to whom the respective goal applied) were to “have confidence in the therapy” (60.5% has helped “quite” or “very much”), “have an easily applicable treatment” (55.6%), and “be able to breathe through my nose more freely” (51.7%). The average PBI-AR global score was 2.19 (SD 1.04) (0–4; with 4 indicating maximum benefit). No significant differences in PBI-AR global score or subscales were found between men and women, poly- and monoallergic patients, or patients with severe versus mild rhinoconjunctivitis. Patients with asthma reported relevant but lower benefit than patients without asthma. CONCLUSION: After 1 year of birch pollen SLIT treatment, patients reported considerable benefit, mainly due to a reduction of physical symptoms and treatment burden.
format Online
Article
Text
id pubmed-7467431
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-74674312020-09-11 Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study Blome, Christine Hadler, Meike Karagiannis, Efstrathios Kisch, Julia Neht, Christopher Kressel, Nora Augustin, Matthias Adv Ther Original Research INTRODUCTION: Sublingual immunotherapy (SLIT) with birch pollen extract has been shown to be an efficacious treatment of allergic rhinitis (AR). An as-yet unanswered question is whether and how clinical benefit translates into patient benefit, i.e. what benefit patients derive from this treatment. METHODS: This 1-year, open, prospective, multicenter, non-interventional study conducted in 75 German centers measured patient-relevant benefit of birch pollen SLIT (Staloral(®) Birch) using the questionnaire “Patient Benefit Index for Allergic Rhinitis (PBI-AR)”. At treatment onset, patients rated the importance of 25 treatment needs; after the first birch pollen season on treatment, goal achievement was evaluated. A preference-weighted benefit index was calculated and its association with gender, asthma, allergy status, and severity of AR symptoms was determined. RESULTS: Mean age of the 291 adult patients was 38.8 years; 58.4% were female. The most important treatment goals were to “be able to stay outdoors without symptoms” (87.3% quite or very important), “no longer have a runny or stuffed-up nose” (86.9%), and “be able to breathe through your nose more freely” (86.9%). The treatment goals with the highest benefit ratings (referring to those patients to whom the respective goal applied) were to “have confidence in the therapy” (60.5% has helped “quite” or “very much”), “have an easily applicable treatment” (55.6%), and “be able to breathe through my nose more freely” (51.7%). The average PBI-AR global score was 2.19 (SD 1.04) (0–4; with 4 indicating maximum benefit). No significant differences in PBI-AR global score or subscales were found between men and women, poly- and monoallergic patients, or patients with severe versus mild rhinoconjunctivitis. Patients with asthma reported relevant but lower benefit than patients without asthma. CONCLUSION: After 1 year of birch pollen SLIT treatment, patients reported considerable benefit, mainly due to a reduction of physical symptoms and treatment burden. Springer Healthcare 2020-04-28 2020 /pmc/articles/PMC7467431/ /pubmed/32342352 http://dx.doi.org/10.1007/s12325-020-01345-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Blome, Christine
Hadler, Meike
Karagiannis, Efstrathios
Kisch, Julia
Neht, Christopher
Kressel, Nora
Augustin, Matthias
Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study
title Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study
title_full Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study
title_fullStr Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study
title_full_unstemmed Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study
title_short Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study
title_sort relevant patient benefit of sublingual immunotherapy with birch pollen allergen extract in allergic rhinitis: an open, prospective, non-interventional study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467431/
https://www.ncbi.nlm.nih.gov/pubmed/32342352
http://dx.doi.org/10.1007/s12325-020-01345-7
work_keys_str_mv AT blomechristine relevantpatientbenefitofsublingualimmunotherapywithbirchpollenallergenextractinallergicrhinitisanopenprospectivenoninterventionalstudy
AT hadlermeike relevantpatientbenefitofsublingualimmunotherapywithbirchpollenallergenextractinallergicrhinitisanopenprospectivenoninterventionalstudy
AT karagiannisefstrathios relevantpatientbenefitofsublingualimmunotherapywithbirchpollenallergenextractinallergicrhinitisanopenprospectivenoninterventionalstudy
AT kischjulia relevantpatientbenefitofsublingualimmunotherapywithbirchpollenallergenextractinallergicrhinitisanopenprospectivenoninterventionalstudy
AT nehtchristopher relevantpatientbenefitofsublingualimmunotherapywithbirchpollenallergenextractinallergicrhinitisanopenprospectivenoninterventionalstudy
AT kresselnora relevantpatientbenefitofsublingualimmunotherapywithbirchpollenallergenextractinallergicrhinitisanopenprospectivenoninterventionalstudy
AT augustinmatthias relevantpatientbenefitofsublingualimmunotherapywithbirchpollenallergenextractinallergicrhinitisanopenprospectivenoninterventionalstudy